Cargando…
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
IMPORTANCE: Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking. OBJECTIVE: To assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in pati...
Ejemplares similares
-
A Case of Confirmed Ceftriaxone-induced Immune Thrombocytopenia
por: Piedra Abusharar, Shady, et al.
Publicado: (2019) -
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study
por: Wagner, Michael J., et al.
Publicado: (2022) -
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma
por: Johnson, Douglas B., et al.
Publicado: (2023) -
Bleeding Complications in Patients with Cancer and COVID 19- Analysis from the COVID 19and Cancer Consortium (CCC19) Registry
por: Shah, Surbhi, et al.
Publicado: (2021) -
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
por: Thompson, Michael A., et al.
Publicado: (2021)